Pathophysiology of blood-brain barrier in brain tumor. Novel therapeutic advances using nanomedicine

Sharma, Hari Shanker; Mureșanu, Dafin F.; Castellani, Rudy J.; Nozari, Ala; Lafuente, José Vicente; Tian, Z. Ryan; Sahib, Seaab; Bryukhovetskiy, Igor; Bryukhovetskiy, Andrey; Patnaik, Ranjana; Wiklund, Lars; Sharma, Aruna

doi:10.1016/bs.irn.2020.03.001

Cited by 44 publications

(16 citation statements)

References 311 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, secondary GBMs develop more commonly in younger patients (mean age <45) because of malignant progression from low-grade glioma [ 1 ]. Etiological risk factors linked to gliomas include, genetic factors, along with exposure to therapeutic ionizing radiation, pesticides, vinyl chloride, smoking, synthetic rubber manufacturing, and petroleum refining industries [ 20 ]. Genetic disorders including Ollier disease, Li-Fraumeni syndrome, and melanoma-neural system tumor syndrome also increase the risk of gliomas in children and adults [ 21 ].…”

Section: Pathophysiology Of Gbm and Role Of Tksmentioning

confidence: 99%

See 1 more Smart Citation

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery

Brar

Jose

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is an aggressive brain tumor with high mortality rates. Due to its invasiveness, heterogeneity, and incomplete resection, the treatment is very challenging. Targeted therapies such as tyrosine kinase inhibitors (TKIs) have great potential for GBM treatment, however, their efficacy is primarily limited by poor brain distribution due to the presence of the blood–brain barrier (BBB). This review focuses on the potential of TKIs in GBM therapy and provides an insight into the reasons behind unsuccessful clinical trials of TKIs in GBM despite the success in treating other cancer types. The main section is dedicated to the use of promising drug delivery strategies for targeted delivery to brain tumors. Use of brain targeted delivery strategies can help enhance the efficacy of TKIs in GBM. Among various drug delivery approaches used to bypass or cross BBB, utilizing nanocarriers is a promising strategy to augment the pharmacokinetic properties of TKIs and overcome their limitations. This is because of their advantages such as the ability to cross BBB, chemical stabilization of drug in circulation, passive or active targeting of tumor, modulation of drug release from the carrier, and the possibility to be delivered via non-invasive intranasal route.

show abstract

Section: Pathophysiology Of Gbm and Role Of Tksmentioning

confidence: 99%

“…GBM originates from glioblastoma stem cells (GSCs) [ 22 ]. They are highly proliferative, have strong tumorigenic abilities, and contribute resistance to radiotherapy by preferentially activating DNA-damage response pathways [ 20 ]. Glioblastoma can induce phenotypic modifications in normal cells.…”

Section: Pathophysiology Of Gbm and Role Of Tksmentioning

confidence: 99%

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery

Brar

Jose

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…[21] These anomalies show a significant effect on growth factor-mediated cell signaling pathways and encourage uncontrolled cell proliferation, inhibiting apoptosis and stimulating angiogenesis. [22]…”

Section: Molecular Pathology Of Gbmmentioning

confidence: 99%

Untitled

2021

AJP

View full text Add to dashboard Cite

Glioblastoma Multiforme (GBM), a highly infiltrative grade IV primary malignant brain tumor, is characterized by poor prognosis which ultimately leads to a high mortality rate. Various restrictions such as inadequate penetration of the drug through the blood-brain barrier, active moieties falling short in achieving accumulation at tumor site, and short circulation half-life make current conventional chemotherapy insufficient in delivering the drug molecules successfully. In an attempt to overcome current modalities, nanotechnology has emerged as an alternative novel therapy for the management of GBM. Nano-therapies such as liposomes, hybrid vesicles, dendrimers, nanogels, nanorods, and nanowires have been developed for the effective treatment and diagnosis of GBM. Nano-therapies have been proven superior to conventional drug delivery due to less toxicity, higher biocompatibility, and enhanced site-specific targeting. In addition, vaccines and immunotherapy have become a promising strategy for efficacious treatment of GBM. This review provides a brief detail about numerous aspects of nano-therapies mediated treatment of GBM, associated risk, and advancement in the field of enhanced brain tumor targeting. The appraisal deals with the triggering factors responsible for GBM and treatment with various immunotherapies and vaccines and elaborates the significant progress that has been made in the arena of nanoparticles, immunotherapies, and vaccines which are implemented for combatting GBM.

show abstract

“…Thus, access to the brain parenchyma may be restricted in brain disorders. On the other hand, breakdown of the BBB has been demonstrated in AD and PD [304][305][306], glioma [307,308], stroke [309] and traumatic brain injury [310], which may facilitate diffusion of nanocarriers from the blood to the brain parenchyma.…”

Section: Targeting the Bbb In Pathological Conditionsmentioning

confidence: 99%

Designing peptide nanoparticles for efficient brain delivery

Duro‐Castaño

Leite

Forth

et al. 2020

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Pathophysiology of blood-brain barrier in brain tumor. Novel therapeutic advances using nanomedicine

Cited by 44 publications

References 311 publications

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery

Untitled

Designing peptide nanoparticles for efficient brain delivery

Contact Info

Product

Resources

About